Table 1:
Clinical baseline information of clopidogrel group and ticagrelor group
| Groups | Clopidogrel group (n=100) | Ticagrelor group (n=100) | t/x2 | P | |
|---|---|---|---|---|---|
| Male [n, (%)] | 55 (55.00) | 57 (57.00) | 0.080 | 0.777 | |
| Age (yr) | 59.34±9.25 | 60.56±8.75 | 0.715 | 0.476 | |
| Body mass index (kg/m2) | 25.89±1.45 | 25.76±1.26 | 0.677 | 0.499 | |
| Total cholesterol (mnol·L−1) | 7.32±1.34 | 7.29±1.60 | 0.144 | 0.886 | |
| Triglyceride (mnol·L−1) | 2.05±1.12 | 1.99±0.97 | 0.405 | 0.686 | |
| 0 | |||||
| Systolic blood pressure (mmHg) | 137.62±15.97 | 135.89±15.08 | 0.788 | 0.432 | |
| Diastolic blood pressure (mmHg) | 95.56±10.05 | 94.04±10.34 | 1.054 | 0.293 | |
| Left ventricular ejection fraction (%) | 50.89±4.57 | 51.09±5.56 | 0.320 | 0.750 | |
| ACS clinical | STEMI | 19 (19.00) | 15 (15.00) | 0.567 | 0.452 |
| classification | NSTEMI | 24 (24.00) | 34 (34.00) | 2.428 | 0.119 |
| (18) [n, (%)] | AUAP | 57 (57.00) | 51 (51.00) | 0.725 | 0.395 |
| PCI treatment (mm) | Maximum stent length | 23.98±6.45 | 24.03±6.27 | 0.056 | 0.956 |
| Minimum stent length | 18.86±3.65 | 19.16±2.89 | 0.859 | 0.391 | |
| Maximum stent diameter | 3.45±1.27 | 3.46±1.84 | 0.045 | 0.964 | |
| Minimum stent diameter | 2.90±0.68 | 2.82±1.34 | 0.532 | 0.595 | |
| Statins were used before treatment | Yes | 0(0.00) | 0(0.00) | 0.000 | 1.000 |
| No | 100(100.00) | 100(100.00) | 0.000 | 1.000 | |